A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Public ClinicalTrials.gov record NCT06717347. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Study identification
- NCT ID
- NCT06717347
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,046 participants
Conditions and interventions
Conditions
Interventions
- Zilovertamab vedotin Biological
- Rituximab Biological
- Cyclophosphamide Drug
- Doxorubicin Drug
- Rituximab Biosimilar Biological
- Prednisone Drug
- Prednisolone Drug
- Vincristine Drug
- Rescue medication Drug
- Methylprednisolone Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 26, 2025
- Primary completion
- Jul 1, 2029
- Completion
- Mar 28, 2032
- Last update posted
- Sep 10, 2026
2025 – 2032
United States locations
- U.S. sites
- 49
- U.S. states
- 28
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USA Mitchell Cancer Institute ( Site 0173) | Mobile | Alabama | 36604 | Recruiting |
| Banner MD Anderson Cancer Center ( Site 0165) | Gilbert | Arizona | 85234 | Recruiting |
| Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167) | Phoenix | Arizona | 85006 | Recruiting |
| The University of Arizona Cancer Center - North Campus ( Site 0124) | Tucson | Arizona | 85719 | Recruiting |
| Providence Medical Foundation-Oncology ( Site 0168) | Fullerton | California | 92835 | Recruiting |
| MemorialCare Health System - Long Beach Medical Center ( Site 9559) | Long Beach | California | 90806 | Recruiting |
| Cancer Blood and Specialty Clinic ( Site 0109) | Los Alamitos | California | 90720 | Recruiting |
| Cedars-Sinai Medical Center ( Site 0115) | Los Angeles | California | 90048 | Recruiting |
| Pacific Hematology Oncology Associates ( Site 0131) | San Francisco | California | 94115 | Recruiting |
| Lutheran Hospital - Cancer Centers of Colorado ( Site 0180) | Golden | Colorado | 80401 | Recruiting |
| Clermont Oncology Center ( Site 0182) | Clermont | Florida | 34711 | Recruiting |
| Bioresearch Partner ( Site 0157) | Hialeah | Florida | 33013 | Recruiting |
| Orlando Health Cancer Institute ( Site 0169) | Ocoee | Florida | 34761 | Recruiting |
| Mid Florida Hematology and Oncology Center ( Site 0172) | Orange City | Florida | 32763 | Recruiting |
| University Cancer & Blood Center, LLC ( Site 0141) | Athens | Georgia | 30607 | Recruiting |
| Cancer Care Specialists of Illinois ( Site 0152) | O'Fallon | Illinois | 62269 | Recruiting |
| Fort Wayne Medical Oncology and Hematology ( Site 0149) | Fort Wayne | Indiana | 46804 | Recruiting |
| Cotton O'Neil Cancer Center ( Site 0108) | Topeka | Kansas | 66606 | Recruiting |
| University of Kentucky ( Site 0106) | Lexington | Kentucky | 40536 | Recruiting |
| Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0163) | Louisville | Kentucky | 40207 | Recruiting |
| Owensboro Medical Health System ( Site 0195) | Owensboro | Kentucky | 42303 | Recruiting |
| CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0184) | Alexandria | Louisiana | 71301 | Recruiting |
| American Oncology Partners, P.A. ( Site 0185) | Bethesda | Maryland | 20817 | Recruiting |
| Karmanos Cancer Institute ( Site 0174) | Detroit | Michigan | 48201 | Recruiting |
| Corewell Health ( Site 0130) | Grand Rapids | Michigan | 49503 | Recruiting |
| The University of Mississippi Medical Center ( Site 0161) | Jackson | Mississippi | 39216 | Recruiting |
| Circuit Clinical - SSM Health Cancer Care DePaul ( Site 0166) | Bridgeton | Missouri | 63044 | Recruiting |
| Truman Medical Center ( Site 0122) | Kansas City | Missouri | 64108 | Recruiting |
| Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0178) | Billings | Montana | 59102 | Recruiting |
| OptumCare Cancer Care ( Site 0121) | Las Vegas | Nevada | 89102 | Recruiting |
| Comprehensive Cancer Centers of Nevada ( Site 0113) | Las Vegas | Nevada | 89169 | Recruiting |
| Cancer Care Specialists ( Site 9582) | Reno | Nevada | 89511 | Recruiting |
| New York Oncology Hematology, P.C. ( Site 0129) | Albany | New York | 12206 | Recruiting |
| Icahn School of Medicine at Mount Sinai ( Site 0164) | New York | New York | 10029 | Recruiting |
| New York Cancer and Blood Specialists ( Site 9000) | Shirley | New York | 11967 | Recruiting |
| East Carolina University ( Site 0159) | Greenville | North Carolina | 27834 | Recruiting |
| Sanford Health Roger Maris Cancer Center ( Site 0189) | Fargo | North Dakota | 58102 | Recruiting |
| Kaiser Permanente Interstate Medical Office - Central ( Site 0181) | Portland | Oregon | 97227 | Recruiting |
| Prisma Health - Upstate ( Site 0158) | Greenville | South Carolina | 29605 | Recruiting |
| Sanford Cancer Center ( Site 0143) | Sioux Falls | South Dakota | 57104 | Recruiting |
| The University of Tennessee Medical Center ( Site 0142) | Knoxville | Tennessee | 37920 | Recruiting |
| Center for Oncology and Blood Disorders ( Site 0153) | Houston | Texas | 77030 | Completed |
| Houston Methodist Cancer Center ( Site 0154) | Houston | Texas | 77030 | Recruiting |
| Joe Arrington Cancer Research and Treatment Center ( Site 0183) | Lubbock | Texas | 79410 | Recruiting |
| University of Virginia Cancer Center ( Site 0138) | Charlottesville | Virginia | 22903 | Recruiting |
| Virginia Cancer Institute ( Site 0148) | Richmond | Virginia | 23229 | Recruiting |
| Blue Ridge Cancer Care ( Site 0132) | Roanoke | Virginia | 24014 | Recruiting |
| Vista Oncology ( Site 4201) | Olympia | Washington | 98506 | Recruiting |
| SSM Health Dean Medical Group ( Site 0140) | Madison | Wisconsin | 53715 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 223 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06717347, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 10, 2026 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06717347 live on ClinicalTrials.gov.